What is Orexo?
Headquartered in Uppsala, Sweden, and established in 1995, Orexo operates at the intersection of traditional pharmacology and modern digital health. The company specializes in developing improved pharmaceutical formulations and digital therapies designed to treat complex conditions, particularly within the substance use disorder and mental health landscapes. By leveraging a dual-track commercialization strategy—operating directly in the United States while utilizing strategic partnerships globally—Orexo maintains a robust footprint in the life sciences industry. Its commitment to addressing unmet medical needs positions it as a vital contributor to the evolving digital therapeutics ecosystem.
How much funding has Orexo raised?
Orexo has raised a total of $141.7M across 4 funding rounds:
Series B
$22.4M
Stock Offering
$35.7M
Debt
$30M
Debt
$53.6M
Series B (2003): $22.4M with participation from Sofinnova Ventures, Crédit Lyonnais Private Equity, Apex Venture Partners, HealthCap Partners, and Auriga Partners
Stock Issuance/Offering (2005): $35.7M led by Undisclosed
Debt (2013): $30M supported by Danske Bank
Debt (2014): $53.6M featuring Undisclosed
Key Investors in Orexo
Sofinnova Ventures
A leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a focus on building transformative innovations from seed to later-stage.
Apex Venture Partners
A specialized investment firm operating within the finance industry, providing strategic capital to support the growth and operational needs of emerging companies.
HealthCap Partners
A private equity firm focused on creative growth capital and real estate solutions, specifically tailored to the strategic requirements of the healthcare sector.
What's next for Orexo?
Looking ahead, Orexo is well-positioned to leverage its recent capital influx to accelerate the development of its digital health pipeline and expand its commercial reach. The company's focus on integrating digital interventions with pharmaceutical solutions represents a high-growth frontier in healthcare. By maintaining its focus on evidence-based outcomes and strategic market penetration, Orexo is poised to capitalize on the increasing demand for accessible, technology-driven mental health solutions. Future growth will likely be defined by the successful scaling of its digital therapeutic platforms and the continued optimization of its global distribution network.
See full Orexo company page
